First-of-Its-Kind Mobile Testing Platform Launched to Manage and Track On-Site COVID-19 Testing

(Toronto, Canada) and Fio Corporation (Toronto, Canada). The Fionet mobile testing and tracking platform has been specifically developed for controlled, rapid response to pandemics. The platform combines handheld devices linked to online AI-powered cloud, automating frontline testing and capturing test results for tracking. Fionet’s rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs that are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.

Flexible and customizable, Fionet enables testing to be expanded beyond the few overburdened medical centers to small clinics, pharmacies, workplaces, airports, nursing homes, schools, etc. and performed at hospital-grade accuracy, in higher volume, faster-speed, and by less-skilled frontline workers. Fionet has a proven, positive impact on one million patients with infectious diseases in over a dozen countries and four continents.

“Community-based testing and real-time tracking is indispensable for combating pandemics like COVID-19. Fionet has already made this happen in the most challenging epidemic regions on the planet and we are now preparing for imminent deployment of our platform with several partners to combat COVID-19 at home and abroad,” said Dr Michael Greenberg, CEO of Fionet Rapid Response Group, a joint venture set up by Relay Medical and Fio Corp.

“The many transformational benefits delivered by Fionet have been validated and documented in several dozen scientific and medical journals. Fionet has successfully reduced testing errors by 23%, achieves 99.5%1 diagnostic accuracy rate compared to expert lab techs, and provides significant economic efficiencies,” said Yoav Raiter, CEO, Relay Medical Corp.

Related Links:
Relay Medical Corp.
Fio Corporation